FlandersBio on Twitter

Follow us on Twitter

Archive for January 2016 - News

Archive for January 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Neurogenesis - Discovery of a new regulatory mechanism

29.01.2016

Bassem Hassan’s* team at VIB/KU Leuven has discovered a previously unknown mechanism that is highly conserved between species and which regulates neurogenesis through precise temporal control of the activity of a family of proteins essential for brain development: the proneural proteins. This mechanism, a simple reversible chemical modification, is critical for the production of a sufficient number of neurons, their differentiation and the development of the nervous system. read more

ABLYNX TO RECEIVE €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY

29.01.2016

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study is to evaluate the safety profile and dosing schedule for this Nanobody. read more

MDxHealth Announces Conference Participation for First Half 2016

28.01.2016

MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016. read more

Galapagos reports results with GLPG1205 in ulcerative colitis

26.01.2016

Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the ORIGIN Phase 2a study with GLPG1205 confirmed good pharmacokinetics, safety and tolerability. The endpoints for efficacy of GLPG1205 in patients with ulcerative colitis (UC), however, were not met. Galapagos will discontinue clinical development in UC. read more

AMATSIGROUP ACQUIRES Q-BIOLOGICALS AND STRENGTHENS ITS OFFERING FOR INTERNATIONAL PHARMACEUTICAL GROUPS

25.01.2016

Amatsigroup, the leading French provider of services for the development of human and veterinary pharmaceutical products, today announces the acquisition of Q-Biologicals, a Belgian company that provides a comprehensive range of biologics process development and biomanufacturing services, from research to clinical phase, for customers in the biopharmaceutical industry. read more

Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares

25.01.2016

Transparency notification to Galapagos NV (Euronext & NASDAQ: GLPG) - Gilead Sciences, Inc. (NASDAQ: GILD) crosses a 10% threshold of Galapagos' voting rights, to a 14.75% shareholding in Galapagos. read more

LindaCare tekent samenwerkingsovereenkomst met Universitair Ziekenhuis Leuven (UZ Leuven)

21.01.2016

Door middel van deze samenwerking willen de partijen het vanop afstand monitoren van patiënten met een implantaat omwille van chronisch hartfalen, verbeteren. read more

ABLYNX ANNOUNCES WARRANT EXERCISE

21.01.2016

GHENT, Belgium, 21 January 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 288,170 common shares have been issued by the Company in exchange for €1,192,292.70 as the result of the exercise of warrants. read more

MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award

21.01.2016

IRVINE, CA, and HERSTAL, BELGIUM - January 21, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that it received the 2016 Frost & Sullivan Global Technology Innovation Award for its commitment to technological innovation to reduce unnecessary prostate biopsies. read more

argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors

20.01.2016

argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that funds advised by subsidiaries of Federated Investors, Inc. (USA) entered into a subscription agreement with argenx to purchase 1,480,420 shares at a price of € 10.79. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print